Citigroup Maintains Buy on Rhythm Pharmaceuticals, Raises Price Target to $142
Benzinga Newsdesk 7 months ago
NewsPrice TargetAnalyst Ratings
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $131 to $142.
Citigroup analyst Samantha Semenkow maintains Rhythm Pharmaceuticals (NASDAQ:RYTM) with a Buy and raises the price target from $131 to $142.